Business Wire

Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 Global Cancer Stream, in partnership with North American Universities.

Share

A year ago, Brenus was selected to participate in CDL Cancer, a global mentorship program for massively scalable, science-based and innovative companies accelerating cancer treatment.

Thanks to its pioneering STC platform, dedicated to developing a new generation of therapeutic cancer vaccines, Brenus stood out during a scientific evaluation with Dr. John Bell (Principal Senior Scientist at Ottawa Hospital Cancer Research Institute & Professor of Medicine & Immunology at University of Ottawa).

Brenus has graduated from the program along with 9 other companies, successfully completing the 4 sessions that took place from October 2023 to June 2024 across North America.

In this program, Brenus came to seek strategic, international guidance for the development of its platform and their lead candidate targeting colorectal cancer.

During each session, the objectives and updates presented were challenged by the CDL community and mentors: successful entrepreneurs, investors, corporate partners, KOLs, and more, all coming from prestigious institutions (University of New York, Oxford, Toronto, British Columbia). The support received was instrumental in validating Brenus Pharma’s roadmap and accelerating the achievement of strategic milestones in R&D (multi-omics and AI), finance and partnerships.

The CDL sessions, based on an interesting “creative destruction” method, allowed us to leverage expertise across the CDL community and anticipate the next key steps to bring our innovation to patients with urgent unmet needs. This year has already been rich in achievements for Brenus, and we will continue to drive operational excellence to bring our company further. We are proud to have up taken the CDL challenge and we thank our mentors for their trust.” said Paul Bravetti, CEO of Brenus Pharma.

About CDL Cancer

This unique CDL-Global stream brings together global leaders and experts across the cancer care continuum to support technology innovations that improve the cancer experience globally, from prevention to diagnosis, treatment, and survivorship.

About the Creative Destruction Lab

The Creative Destruction Lab (CDL) is a program for massively scalable, science-based companies. The nine-month program employs an objectives-based mentoring process with the goal of maximizing equity-value creation. The CDL is particularly suited to early stage companies with links to university research labs. Launched in 2012 at the Rotman School of Management at the University of Toronto, the program has now expanded with locations in Vancouver, Calgary, Montreal, Halifax, and New York City.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240627958275/en/

Contacts

Marion BRUN, contact@brenus-pharma.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ansys and IonQ Are Bringing the Power of Quantum to the $10 Billion Dollar Computer-Aided Engineering Industry6.11.2024 22:10:00 CET | Press Release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, and Ansys (Nasdaq: ANSS), have joined forces to integrate quantum computing into the $10B computer-aided engineering (CAE) industry.* Together, IonQ and Ansys aim to accelerate simulation, expand high-fidelity design exploration, and reduce product development timelines, enabling faster market entry for innovative products. This partnership aims to make simulation accessible to both quantum experts and non-experts, with the goal of enhancing enterprise value and streamlining product development processes. Ansys solutions are used in product development across industries and account for a significant portion of all modeling and simulation in the CAE market. As IonQ’s quantum computers advance and outpace classical systems on specific tasks, integrating them with Ansys’ technology for complex simulations will open the door to new discoveries and innovations. With these advancements, Ansys will gain access to critical infrastr

Pure Lithium Announces New York Series B Roadshow6.11.2024 21:10:00 CET | Press Release

Pure Lithium Corporation, a disruptive Boston-based vertically-integrated lithium metal battery technology company, is pleased to announce that it will conduct a roadshow in New York the week of November 18, 2024 to promote its $75M to $100M Q1 2025 Series B fundraise. The funds will support the scale-up of the Company’s technology towards commercial lithium metal battery production and a potential Initial Public Offering of the company. Lithium metal is the "holy grail" of energy storage, a step change beyond today's lithium-ion battery. It does not require graphite, nickel, cobalt and manganese, eliminating dependence on China and enabling local battery hubs in favorable jurisdictions for the first time ever. Since opening its Boston lab in January of 2021, Pure Lithium has made impressive strides towards commercializing the lithium metal battery. This year, the Company raised $20M in its Series A.5 with Oxy Low Carbon Ventures as the lead investor. Major progress has been made on a

Perma-Pipe International Holdings, Inc. Announces $15 Million in Contract Awards in the Americas and Middle East Regions6.11.2024 20:01:00 CET | Press Release

Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced $6 million in new project awards in the MENA region. Additionally, the company announced $9 million in new project awards in the Americas, demonstrating continual improvement in the region. These new project awards will utilize Perma-Pipe’s anti-corrosion coatings capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. These new project awards further complement our backlog, which has experienced considerable growth. Backlog was $75.0 million at July 31, 2024 and is now in excess of $100.0 million. Marc Huber, Sr. Vice President for Perma-Pipe’s Americas region, commented, “We are delighted with these awards which demonstrate the buoyancy in the Americas market and the continual strengthening of our position in the USA and Canada.” Saleh Sagr, Sr. Vice President for Perma-Pipe’s MENA region, commented, “The latest awards in MENA largely

Mouser Electronics Examines the Human-Centric Revolution of Industry 5.06.11.2024 18:11:00 CET | Press Release

Mouser Electronics, Inc., the global authorized distributor renowned for providing the latest in electronic components and industrial automation solutions, today unveiled the newest chapter in its Empowering Innovation Together (EIT) technology series, which focuses on the emerging landscape of Industry 5.0. In this next phase of industrialization, human, environmental, and social considerations will factor into the advanced technology, robotics, and smart machines on the factory floor of the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241106421709/en/ For the last several decades, the manufacturing world has been integrating robots into factory control systems—a move compared to a fourth industrial revolution and named Industry 4.0. Now, Industry 5.0 puts people at the heart of manufacturing bringing technology and humanity closer together. (Graphic: Business Wire) Building on the technological advancements of In

Building a World-Class Synthetic Biology Lab: Asymchem’s Self-Developed STAR System Empowers Protein Design6.11.2024 17:00:00 CET | Press Release

Asymchem (stock code: 002821.SZ/6821.HK), a leading global contract development and manufacturing organization (CDMO), has created an artificial intelligence (AI) platform to address key challenges in protein design. This platform, known as STAR (Sequence Recommendation via Artificial Intelligence), was successfully developed by Asymchem’s Center of Synthetic Biology Technology (CSBT) and AI team. The team published a paper titled “STAR: A Web Server for Assisting Directed Protein Evolution with Machine Learning” in ACS Omega, detailing the system’s ability to integrate multiple machine learning models and sequence encoding methods. One major challenge in protein engineering is the number of mutations that need to be generated and screened. This can take anywhere from 3 to 6 months. STAR dramatically accelerates this process. By leveraging machine learning, the platform quickly identifies critical regions for mutation. This reduces the number of experimental samples to just a few hundr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye